Literature DB >> 31507036

Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018.

Ju Yup Lee1,2, Nayoung Kim1,3, Ryoung Hee Nam1, Soo In Choi1, Jung Won Lee4, Dong Ho Lee1,3.   

Abstract

BACKGROUND: Antimicrobial resistance of Helicobacter pylori (H pylori) affects the efficacy of eradication therapy. The aim of this study was to estimate the prevalence of primary and secondary resistance of H pylori isolates to antibiotics in Korea.
METHODS: The present study was performed from 2003 to 2018. Primary resistance was evaluated in 591 patients without any history of eradication and secondary resistance in 149 patients from whom Helicobacter pylori was cultured after failure of eradication. A minimal inhibitory concentration test was performed for amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and rifabutin using the agar dilution method.
RESULTS: An increase in the primary resistance rate was found in clarithromycin (P < .001), metronidazole (P < .001), and both levofloxacin (P < .001) during the study period. The primary resistance rates of amoxicillin and tetracycline were low and stable during the study period. The secondary resistance rate significantly increased in metronidazole and levofloxacin (P = .022 and .039, respectively).
CONCLUSIONS: The primary and secondary resistance rates of clarithromycin, metronidazole, and levofloxacin for Helicobacter pylori in Korea were high and increased over time. However, the primary and secondary resistance rates of amoxicillin and tetracycline were low and stable over time. These results will help in selecting effective eradication regimens of H pylori in Korea in the future.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Helicobacter pylorizzm321990; antibiotics; prevalence; resistance

Mesh:

Substances:

Year:  2019        PMID: 31507036     DOI: 10.1111/hel.12660

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  9 in total

Review 1.  Management of Helicobacter pylori Infection: A Comparison between Korea and the United States.

Authors:  Sung Eun Kim; Joo Ha Hwang
Journal:  Gut Liver       Date:  2021-10-25       Impact factor: 4.321

2.  Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication.

Authors:  Young Woon Chang; Ga Young Shin; Jung-Wook Kim; Jin-Chang Moon; Eun Jee Chang; Chi Hyuk Oh; Jae-Young Jang
Journal:  Dig Dis Sci       Date:  2021-03-23       Impact factor: 3.199

Review 3.  Update on quinolone-containing rescue therapies for Helicobacter pylori infection.

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  World J Gastroenterol       Date:  2020-04-21       Impact factor: 5.742

4.  Eradication Treatment of Helicobacter pylori Infection Based on Molecular Pathologic Antibiotic Resistance.

Authors:  Chun Gao; Shi-Yu Du; Long Fang; Yan-Hua Fan; Ai-Ping Song; Huang Chen
Journal:  Infect Drug Resist       Date:  2020-01-07       Impact factor: 4.003

Review 5.  Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review.

Authors:  Javier P Gisbert
Journal:  Pathogens       Date:  2020-12-28

6.  Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.

Authors:  Young-Il Kim; Jong Yeul Lee; Chan Gyoo Kim; Boram Park; Jin Young Park; Il Ju Choi
Journal:  BMC Gastroenterol       Date:  2021-03-02       Impact factor: 3.067

7.  Comparison of eradication rates of moxifloxacin-rifabutin triple therapy and bismuth quadruple therapy as second-line regimens in patients with peptic ulcers.

Authors:  Chang Min Lee; Seong Je Kim; Se In Hah; Ji Yoon Kwak; Jung Woo Choi; Hyun Chin Cho; Chang Yoon Ha; Ok Jae Lee; Woon Tae Jung
Journal:  Health Sci Rep       Date:  2022-08-23

8.  A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations.

Authors:  Su Jin Kim; Sam Ryong Jee; Moo In Park; Kyoungwon Jung; Gwang Ha Kim; Moon Won Lee; Jin Lee; Jin Seok Jang; Myeongseok Koh
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

9.  Current status of Helicobacter pylori resistance to Clarithromycin and Levofloxacin in Malaysia-findings from a molecular based study.

Authors:  Suat Moi Puah; Khean Lee Goh; Heng Kang Ng; Kek Heng Chua
Journal:  PeerJ       Date:  2021-06-09       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.